tavaborole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4877 174671-46-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • AN-2690
  • AN 2690
  • tavaborole
  • kerydin
  • AN2690
The mechanism of action of tavaborole is inhibition of fungal protein synthesis. Tavaborole inhibits protein synthesis by inhibition of an aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS).Tavaborole has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections.
  • Molecular weight: 151.93
  • Formula: C7H6BFO2
  • CLOGP: 1.54
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 29.46
  • ALOGS: -1.13
  • ROTB: 0
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.643 Moderate 0.76
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.594 Moderate 0.76
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 81.846 10^-6 cm/s Moderate 0.76
dh-clint Dog hepatocyte intrinsic clearance 27.040 uL/min/10^6 cells Moderate 0.76
dppb Dog plasma protein binding (% unbound) 9.360 % Moderate 0.76
fcs-ppb Fetal calf serum protein binding (% unbound) 17.120 % Moderate 0.76
herg hERG pIC50 4.383 pIC50 Moderate 0.76
hh-clint Human hepatocyte intrinsic clearance 17.458 uL/min/10^6 cells Moderate 0.76
hlm-clint Human liver microsomal intrinsic clearance 22.961 uL/min/mg protein Moderate 0.76
hppb Human plasma protein binding (% unbound) 8.060 % Moderate 0.76
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TGFBR1 18
kinase-selectivity-class AXL,EIF2AK3,GRK2,RIPK1 4
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.521 Moderate 0.76
mh-clint Mouse hepatocyte intrinsic clearance 84.528 Moderate 0.76
mppb Mouse plasma protein binding (% unbound) 9.760 Moderate 0.76
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.984 Moderate 0.76
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 9.360 % Moderate 0.76
rh-clint Rat hepatocyte intrinsic clearance 59.156 uL/min/10^6 cells Moderate 0.76
rh-fuinc Rat hepatocyte fraction unbound in incubation 69.470 % Moderate 0.76
rppb Rat plasma protein binding (% unbound) 7.930 % Moderate 0.76
solubility-dd Solubility at pH 7.4 in DMSO 36.224 uM Moderate 0.76

Approvals:

DateAgencyCompanyOrphan
July 7, 2014 FDA ANACOR PHARMS INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D01AE24 DERMATOLOGICALS
ANTIFUNGALS FOR DERMATOLOGICAL USE
ANTIFUNGALS FOR TOPICAL USE
Other antifungals for topical use
FDA CS M0002832 Boron Compounds
FDA MoA N0000000150 Protein Synthesis Inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
FDA EPC N0000191279 Oxaborole Antifungal
CHEBI has role CHEBI:35718 antifungal agent
CHEBI has role CHEBI:48001 protein synthesis inhibitor
CHEBI has role CHEBI:77953 EC 6.1.1.4 (leucine—tRNA ligase) inhibitor

Related Drugs by ATC class:

D01AE Other antifungals for topical use 23 drugs
2-(4-chlorphenoxy)-ethanolamorolfinebromochlorosalicylanilidebutenafinechlorphenesin carbamateciclopiroxdimazoleethyl hydroxybenzoateflucytosinehaloproginliranaftatemethylrosaniline show all 23 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Onychomycosis due to Trichophyton mentagrophytes indication 23549005
Onychomycosis due to Trichophyton rubrum indication 56922006
Onychomycosis due to dermatophyte indication 402134005
Onychomycosis of toenails indication 403059006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.49 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Carbonic anhydrase 2 Enzyme Ki 6.33 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 5.70 CHEMBL
Leucine-tRNA ligase Enzyme INHIBITOR CHEMBL CHEMBL
Carbonic anhydrase Enzyme Ki 7.14 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 7.05 CHEMBL
Leucine--tRNA ligase, cytoplasmic Enzyme Ki 5.73 CHEMBL

External reference:

IDSource
D10169 KEGG_DRUG
4033648 VUID
N0000191084 NUI
4033648 VANDF
CHEMBL443052 ChEMBL_ID
C512998 MESH_SUPPLEMENTAL_RECORD_UI
DB09041 DRUGBANK_ID
1543173 RXNORM
222423 MMSL
30392 MMSL
340008 MMSL
399962 MMSL
015655 NDDF
716264009 SNOMEDCT_US
763516005 SNOMEDCT_US
C3642427 UMLSCUI
CHEBI:77942 CHEBI
A1CF8 PDB_CHEM_ID
9425 INN_ID
11499245 PUBCHEM_CID
K124A4EUQ3 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tavaborole HUMAN PRESCRIPTION DRUG LABEL 1 21922-020 SOLUTION 43.50 mg TOPICAL ANDA 24 sections
Tavaborole HUMAN PRESCRIPTION DRUG LABEL 1 46708-467 SOLUTION 43.50 mg TOPICAL ANDA 23 sections
tavaborole HUMAN PRESCRIPTION DRUG LABEL 1 51862-690 SOLUTION 43.50 mg TOPICAL ANDA 28 sections
Tavaborole HUMAN PRESCRIPTION DRUG LABEL 1 62135-663 SOLUTION 43.50 mg TOPICAL ANDA 16 sections
Tavaborole HUMAN PRESCRIPTION DRUG LABEL 1 62332-467 SOLUTION 43.50 mg TOPICAL ANDA 23 sections
TAVABOROLE HUMAN PRESCRIPTION DRUG LABEL 1 69097-686 SOLUTION 43.50 mg TOPICAL ANDA 25 sections
Tavaborole HUMAN PRESCRIPTION DRUG LABEL 1 69238-1657 SOLUTION 43.50 mg TOPICAL ANDA 24 sections
Tavaborole HUMAN PRESCRIPTION DRUG LABEL 1 70771-1826 SOLUTION 43.50 mg TOPICAL ANDA 1 sections
Tavaborole HUMAN PRESCRIPTION DRUG LABEL 1 72578-102 SOLUTION 43.50 mg TOPICAL ANDA 24 sections